Frontotemporal lobar degeneration (FTLD), formerly called Pick's disease, is a progressive neurodegenerative disease affecting the frontal and anterior temporal lobes. In 1998, consensus criteria for FTLD defined three clinical syndromes, all hypothesized to be linked by underlying similarities in neuropathology. These include frontotemporal dementia (FTD) (also called the frontal variant of FTD), semantic dementia (also called the temporal variant of FTD), and nonfluent aphasia. Despite some overlap in regional atrophy with Alzheimer's disease (AD), the distinctive anatomic patterns of neurodegeneration seen with the three major FTLD subtypes allow their separation from most patients with AD and from each other based upon clinical features and neuroimaging patterns. The neuropathology associated with FTLD is distinctive from AD and does not involve aggregation of Ab-42.
Note: Text referenced in the Quintessentials Preferred Responses, which appear later in this issue, is indicated by gray shading throughout the text.
OVERVIEW
Once considered rare, recent work suggests that frontotemporal lobar degeneration (FTLD) is a common cause for dementia, particularly in patients younger than 70 years. FTLD typically presents in patients who are between 45 and 65 years of age, and a positive family history is found in up to 40% of cases. FTLD is at least as likely as early-onset Alzheimer's disease (AD), with the prevalence for FTLD and AD approximately 15 per 100,000 persons aged between 45 and 64 years (Ratnavalli et al, 2002) . In fact, Knopman and colleagues (2004) have recently shown that FTLD may be more common than AD in patients younger than 60 years. Other studies sug-gest that FTLD accounts for up to 20% of all patients with degenerative dementias (Brun, 1987; Neary et al, 1988) .
Although FTLD is still described as a single diagnostic entity, recent findings suggest that frontotemporal dementia (FTD), semantic dementia (SD), and nonfluent aphasia (NFA) differ in prevalence, age of onset, sex distributions, genetic susceptibilities, coassociations with other degenerative conditions, and neuropathologic features. For example, FTD accounts for approximately 56% of all FTLD cases, is male predominant by two to one, has the earliest age of onset (approximately 58 years at diagnosis), progresses the most rapidly from time of diagnosis (3.4 years from diagnosis to death), has the highest genetic susceptibility (up to 20% of cases show an autosomal dominant pattern of inheritance), has a strong association with ALS, and often shows equal percentages of cases with ubiquitin or tau inclusions postmortem. SD accounts for less than 20% of all FTLD cases, has a similar age of onset to FTD, shows the slowest rate of progression of all the FTLD subtypes (5.2 years from diagnosis to death), has a low percentage of cases with an autosomal dominant pattern of inheritance, and usually shows ubiquitin inclusions postmortem (Johnson et al, 2005; Roberson et al, 2005) . Finally, NFA accounts for approximately 25% of all FTLD cases, is intermediate in rates of progression (4.3 years from diagnosis) and genetic propensity, has a high association with corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP), and cases nearly always show tau inclusions postmortem (Josephs et al, 2006) (Figure 4-1) .
Arnold Pick (1892) is credited as the first clinician to describe the focal atrophy resulting in a set of behavioral symptoms that are now ascribed to FTLD. Most of Pick's original cases had focal temporal atrophy and would now be classified as SD, although he did describe cases with focal frontal atrophy. The hallmarks of ''Pick's disease'' are intraneuronal inclusions seen upon pathologic investigation, first described by Alois Alzheimer (1911) . Despite the recognition of FTLD as a cause for neurodegeneration early in the 20th century, there was a paucity of clinical reports and studies of focal cerebral atrophy until the 1980s. Investigators in Lund, Sweden, and Manchester, England (Gustafson, 1987; Neary et al, 1986) , rekindled studies into Pick's disease and began to report on patients with focal frontal lobe degeneration. In parallel with these reports, patients with ''primary progressive aphasia'' were described in whom asymmetric degeneration of the left hemisphere was found. As with the symmetric frontal cases described as ''FTD,'' non-AD pathology was found in most cases of primary progressive aphasia. Many of the aphasia patients in these original cohorts would now be classified as suffering from either NFA or SD.
The advent of neuroimaging in the late 1980s and early 1990s was associated with a rise in reports of patients with atrophy of the frontal and anterior temporal lobes, in conjunction with non-Alzheimer pathology; in many of these cases, classic Pick bodies were not found (Brun, 1987; Knopman et al, 1990; Mann et al, 1993) . In the early 1990s, many more cases were reported in the United States (Jagust et al, 1989; Miller et al, 1991) . Eventually, FTLD emerged as a general term to 88 FIGURE 4-1 Heterogeneity of atrophy in frontotemporal lobar degeneration (FTLD) subtypes. T1-weighted MRI scans (coronal slices) of three patients, each with a unique FTLD subtype. Patients with frontotemporal dementia (FTD) show primarily bilateral frontal atrophy, patients with nonfluent aphasia (NFA) show primarily left frontal atrophy, and patients with semantic dementia (SD) show asymmetric temporal lobe atrophy.
KEY POINTS:
A FTLD has three subtypes: frontotemporal dementia (FTD), semantic dementia, and nonfluent aphasia. describe this disease. Genetics remain an important risk factor for FTLD, despite the fact that the majority of cases appear to be sporadic in origin. Genetic studies have proven fruitful, and several genes have been linked to the disease.
DIAGNOSING FRONTOTEMPORAL LOBAR DEGENERATION
Relative to other dementias, FTLD has been considered a disorder that is difficult to diagnose with clinical accuracy. Victor and Ropper state, ''Whether the diagnosis is possible during life is doubtful, our clinical predictions as to the existence of the pathologic changes have been erratic'' ( Victor and Ropper, 2001 ). Merritt's textbook notes ''the consensus of opinion is that the differential diagnosis can be made only at biopsy and necropsy'' (Rowland, 2000) . Indeed, both AD and FTLD have insidious onset; produce a progressive dementia syndrome that can include memory deficits, executive dysfunction, and language impairment; and cause alterations in behavior that make the two disorders difficult to differentiate (Varma et al, 1999) .
While definitive differential diagnosis of FTLD and AD continues to rely on pathology, accurate diagnosis during life has recently progressed at a rapid pace. By the mid-1990s reports were showing that FTLD could be reliably differentiated from AD (Miller, 1997; Read et al, 1995) . In AD, degeneration most commonly begins in the medial temporal lobes, leading to episodic memory deficits and an inability to learn new information. As the disease progresses, other cognitive, social, and emotional impairments are observed. In FTLD, in contrast, degeneration starts in the frontal and anterior temporal lobes, and early symptoms include deficits in executive or language function, often coupled with relatively intact episodic memory.
One of the primary complications related to FTLD diagnosis is the anatomical heterogeneity of the disease. The 1998 consensus criteria for FTLD take into consideration this heterogeneity by dividing this disorder into three different subtypes: FTD, NFA, and SD (Neary et al, 1998) . These three clinical syndromes were differentiated primarily on the relative degeneration seen in the frontal and temporal lobes and the right and left hemispheres ( Table 4-1) . Individuals with FTD show primarily right frontal involvement and present with behavioral abnormalities such as disinhibition, apathy, emotional blunting, and lack of insight. Patients with NFA have selective left fronto-insular degeneration and present with agrammatism, hesitant, nonfluent speech output, and speech apraxia. With SD, which is a temporally predominant disorder, two syndromes emerge: SD patients with predominantly left temporal degeneration have profound anomia associated with progressive loss of conceptual knowledge of words, while predominantly right temporal cases are associated with deficits in empathy and knowledge about people's emotions.
Patients with FTLD often overlap with three other disorders: corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), and FTD with motor neuron disease (FTD-MND). Traditionally, CBD was defined by the presence of asymmetric parkinsonism with dystonia, rigidity, limb apraxia, and a ''useless or alien'' limb. Pathologic examination demonstrates neuronal inclusions with tau present in astrocytes and neurons. More than half of the cases diagnosed with CBD pathologically do show no antemortem rigidity or apraxia (Boeve et al, 1999) . Traditionally, PSP has been described as a movement disorder associated with falls, ophthalmoplegia, axial rigidity, and a frontal dementia. Like CBD,
KEY POINT:
A tau inclusions are seen postmortem. Recently, it has become evident that most patients with NFA show PSP or CBD postmortem. Some patients with FTD also show PSP or CBD, but these entities are rarely seen pathologically with SD (Kertesz and Munoz, 2000; Mathuranath et al, 2000) .
The first indication that dementia might be related to motor neuron disease (MND) dates back to the 1920s (Meyer, 1929) . Several reports were published in the 1980s (Clark et al, 1986; Hudson, 1981; Mitsuyama et al, 1984; Morita et al, 1987; Salazar et al, 1983) , and a link with FTD was suggested by Neary and colleagues (1990) . Generally these patients start with dementia symptoms, primarily behavioral changes such as disinhibition. Shortly after the onset of dementia, patients develop weakness and wasting of limb 90 1996) . High misdiagnosis rates have implications for FTLD and AD: patient misclassification confounds drug trials, while muddying clinical and imaging studies of both disorders, leading to inappropriate treatment. Also, anticholinesterase therapies effective for AD have no rational basis as a therapy for FTLD since patients with FTLD often have normal cholinergic cell counts in the nucleus basalis of Meynert (Francis et al, 1993) . Treatment with anticholinesterase compounds can lead to irritability, agitation, and worsening of swallowing difficulties secondary to increased salivary secretions (Chow, 2005; Perry and Miller, 2001; Swartz et al, 1997) . New approaches to AD include targeting Ab-42 synthesis and breakdown, potentially toxic therapies unlikely to help a patient with FTLD, where Ab-42 deposition is not relevant. Emergence of these molecule-specific therapies for AD, along with the new potential therapies for AD, underscores the importance of accurate diagnosis.
PRESENTATION OF FRONTOTEMPORAL LOBAR DEGENERATION
Frontotemporal Dementia Subtype FTD, the prototypical FTLD syndrome, is characterized by a multitude of behavioral changes that often herald the onset of the dementia. These include alterations in social decorum and personal regulation including disinhibition, apathy, overeating, emotional blunting, personality changes toward coldness and submissiveness, repetitive motor behaviors, and impairment in judg-ment and insight. With these behavioral changes, deficits in executive control emerge and patients have problems with planning, organizing, shifting patterns, and generating ideas. As FTD may be considered a midlife problem of adjustment or a psychiatric disorder, patients often do not reach the neurologist until they have made profound lapses in financial or interpersonal judgment. Unlike in AD, where family and acquaintances are sympathetic due to the sparing of social decorum, colleagues and family may resent patients with FTD because of their rudeness, coldness, and deficits in social modulation. Approximately 15% of patients develop ALS, and extrapyramidal deficits are common. Both structural and functional imaging are helpful and typically show abnormalities in the right greater than the left frontal regions. The ventral and medial frontal and insular regions-all paralimbic structures-are hit early in FTD, driving the disinhibition, apathy, and eating disorders, and this atrophy is usually evident by the time that the patient presents to the office (Case 4-1).
Semantic Dementia Subtype
SD is a temporally predominant syndrome that attacks asymmetrically either the left or the right temporal lobe. In our experience, left-sided cases are more commonly recognized than are cases that begin on the right-side. In classic SD, patients show problems with word finding, sometimes with nouns more than verbs. Speech remains fluent, but anomia worsens and patients show trouble not only in naming words, but even in recognizing words. Compulsive interest in visually appealing objects is common, sometimes leading to compulsive playing of card games such as solitaire. As the disease spreads to the right side patients begin to have problems recognizing emotions in others. Eventually
KEY POINTS:
A FTD is characterized by a multitude of behavioral changes, including dramatic changes in social decorum and personal regulation.
A Semantic dementia is a temporally predominant syndrome that attacks asymmetrically either the left (more common) or the right temporal lobe.
Case 4-1
A 52-year-old male tax accountant began to embezzle money at work, regularly withdrawing $150 from his office account in order to buy pornography on the Internet. Despite making no effort to hide his embezzlement, his rationale for taking the money was that he wanted to hide this sexual activity from his wife. Around the time that he was caught by his supervisor, female employees complained that the patient stared inappropriately at them and often made rude comments about their breasts or weight. His work had dramatically deteriorated, and rather than working on his accounts, he spent most of the day at work shuffling papers, reading magazines, or downloading pornography onto his computer. He was fired but made no attempts to find a new job. His wife and children reported that over the past year he had lost interest in them and watched television without speaking when at home. He developed a strong desire for ice cream and gained 20 lbs. His manners deteriorated, and he stuffed his mouth, often choking at the dinner table. He insisted on eating food on his plate in a specific order, often with his hands. Family history revealed that his father and brother had died from ''Lou Gehrig's disease.'' Upon examination, the patient was profoundly apathetic and indifferent and denied embezzling money, passively shrugging his shoulders when his tearful wife described his problems in the workplace and at home. When asked about his future, he was very optimistic, stating that he could make lots of money as a private accountant if he wanted. Basic neurologic examination revealed pathologically brisk snout and jaw jerks. Fasciculations, as well as subtle atrophy and weakness, were evident in the arms and legs. Plantar responses were flexor.
On neuropsychological testing he scored 27/30 on the Mini-Mental State Examination (MMSE), missing one point each for the name of the hospital, the season, and for spelling world backwards. Speech was fluent, but the patient insisted on telling off-color jokes. He commented on the examiner's old age. He failed badly on word generation, getting six d words and nine animals with normal being 12 d words and 15 animals. On the Trail-Making Test, Trails B, he made frequent perseverative errors and was unable to abstract on proverbs, often repeating the proverb back to the examiner rather than offering an interpretation. He correctly named 55 of 60 words on the Boston Naming Test. He copied complex designs without error and remembered most of the designs after 5 minutes. Similarly, he remembered seven of nine words in 5 minutes. MRI revealed mild right greater than left fronto-insular atrophy. EMG was normal. Blood was sent for tau, superoxide dismutase, and progranulin mutations, all of which were absent (Figure 4-2) . Within 6 months, the patient was even more apathetic and unable to speak. He spent most of his time counting airplanes in his continued on page 91 " FRONTOTEMPORAL DEMENTIA prosopagnosia and multimodality agnosia for objects develop (Case 4-2).
Nonfluent Aphasia Subtype
A disorder that begins with deficits in speech or language, NFA is insidious in onset. Often, the patient becomes aware of his or her deficits before others have noticed changes. NFA emerges with decreased output for words, while soon thereafter, shortened phrase lengths and deficits in articulation develop. The use of nouns remains intact, but deficits in the understanding of grammar are common. Many patients exhibit speech apraxia, which is characterized by a deficit in articulatory planning resulting in an inability to command the speech musculature to produce sounds in a proper sequence. Social decorum remains intact throughout most of the illness, although some patients evolve to an FTD syndrome. Motor disorders characteristic of CBD or PSP become common several years after the onset of NFA. Some patients evolve from NFA to classic CBD or PSP over a fairly short period of time. Most patients with NFA show tau pathology at autopsy (Case 4-3).
PATHOLOGIC FINDINGS IN FRONTOTEMPORAL LOBAR DEGENERATION
Pathologically, two major types of changes are observed in FTLD: gross morphologic atrophy in the frontal and anterior temporal lobes, and microscopic changes, including any or all of the following: gliosis, inclusion bodies, swollen neurons, and microvacuolation. Increasingly, the focus of research is upon whether the inclusions within neurons or glia consist of tau or ubiquitin.
Gross Anatomical Changes
In FTLD, a mild to severe decrease in overall brain weight and atrophy of the frontal and temporal lobes occur. Symmetric atrophy of the frontal lobes generally indicates FTD, while asymmetric atrophy is consistent with NFA (frontal lobes) and SD (temporal lobes). Thinning of the cortical ribbon and discoloration of white matter may also be present. In rarer cases, atrophy may extend into the parietal lobes, amygdala, hippocampus, insula, thalamus, and basal ganglia (head of the caudate nucleus) (Mann and South, 1993) . Ventricular enlargement may also be observed, as well as pallor of the substantia nigra, atrophy of the anterior nerve roots, and discoloration of the lateral funiculus in the spinal cord.
Microscopic Findings
In classic Pick's disease atrophy tends to be extreme. Much of the gross 93 backyard. Swallowing liquids became difficult, and aspiration became frequent. He died 9 months after diagnosis as a result of pneumonia. Pathology showed extensive gliosis and spongiosus of the frontal cortex. Ubiquitin and TDP-43-positive, tau-negative inclusions were seen in the dentate gyrus of the hippocampus. FTD-MND was diagnosed.
Comment. This patient presented with classic signs of FTD, including poor judgment, lack of insight, disinhibition, apathy, and compulsive overeating, which led him to be fired from his job and alienated from his wife. Like many patients with FTD, despite a relatively intact MMSE visuospatial and language function, he failed badly on tasks of generation and executive function. With a strong family history of ALS, it is not surprising that the patient, soon after demonstrating symptoms of FTD, also went on to develop ALS with evidence for dysphagia and showed pathology suggestive for FTD-ALS with ubiquitin and TDP-43-positive inclusions.
Continued from page 90
KEY POINTS:
A Nonfluent aphasia begins with deficits in speech or language; many patients evolve from nonfluent dementia to classic corticobasal degeneration or progressive supranuclear palsy.
A Symmetric atrophy of the frontal lobes generally indicates FTD, while asymmetric atrophy is consistent with nonfluent aphasia (frontal lobes) and semantic dementia (temporal lobes).
Case 4-2
A talented engineer-inventor began to have trouble finding names for people and objects. He continued to design complex sprinkler systems but had trouble filling out paper orders, making frequent spelling mistakes. Inexplicably, he was caught stealing a pair of shiny earrings from a department store. Soon afterward he began to walk the streets, spending many hours looking for coins. While at home he began to play solitaire compulsively for 6 hours per day. He developed a new interest in tennis, and his game steadily improved. He stopped working as an inventor but obtained a newspaper delivery job and learned and remembered a complex route for delivering papers. There was no family history of dementia.
Examination revealed a bright and attentive man who spoke rapidly. Behavior was appropriate except for occasional interruptions of the examiner to complain that his driver's license had been taken away. Basic neurologic examination was normal. His MMSE score was 24/30. The items missed were two of three words on memory, naming of the watch and pen, and two items on the three-step command. Speech was fluent but slightly empty. Comprehension was mildly impaired due to deficits in understanding some words. Working memory was normal with eight numbers repeated backwards. He generated only four animals in 1 minute and 10 d words. The Trail-Making Test, Trails B, was performed quickly and correctly, but he could not interpret proverbs.
Copying was precisely performed without error, and after 10 minutes he remembered 16 of 17 points on the drawing. He had trouble with learning a list of nine words, remembering only four after five trials. He retained these four words after 10 minutes. He correctly named 16 of 60 words on the Boston Naming Test, missing all of the animals except for dog. Naming for most items was not improved by category clues or multiple choice. Subtle deficits in recognizing facial emotions for fear and sadness were evident (Figure 4-3) . continued on page 93 " FRONTOTEMPORAL DEMENTIA atrophy seen at pathology is a result of a severe and often complete loss of large pyramidal cells in cortical layer III, and the small pyramidal and nonpyramidal cells of layer II (Mann et al, 1993) . Pyramidal cells in layer V may also be shrunken. White matter changes include loss of myelin and axons. Remaining neurons also show two distinctive histologic features: swelling (called ballooned or Pick cell) and an inclusion within the perikaryon, most often in layer II (Pick body). Pick bodies are usually found in limbic (greatest concentration is in the amygdala and hippocampus, including the dentate gyrus), paralimbic, and ventral temporal lobe cortex, but may also be seen in anterior frontal and dorsal temporal lobes. They are rarely found elsewhere in the brain. Pick bodies are composed of randomly arranged filaments of the tau protein, which is an axonal protein involved in microtubule assembly. Despite the origins of the FTLD classification, only a minority of patients diagnosed with FTLD will show the classic Pick pattern at autopsy. Furthermore, even in patients with tau inclusions, the majority will not show the classic Pick body that stains positive with silver stains (argyrophilic) (Figure 4-5) .
In patients with classic ALS and FTD (called FTD-MND), a second histologic pattern is observed. Generally, these patients show loss of large pyramidal cells, microvacuolation, and mild gliosis (Neary et al, 2000) . Substantia nigra is pale, with intense reactive fibrous astrocytosis. Inclusions are taunegative but ubiquitin-positive and found throughout the frontal cortex and hippocampus (dentate gyrus). The hypoglossal nucleus in the brain stem also shows atrophy. Atrophy tends to be less severe than in cases with tau inclusions.
Finally, many cases of FTLD, even those without clinical evidence for ALS, show non-tau pathology (Neary et al, 2000) , and many of these cases show ubiquitin-only (tau and -synuclein negative) immunoreactive neuronal changes (FTLD-ubiquitin-only [FTLD-U] ). Recently, the identity of the ubiquitinated protein has been discovered. In FTLD-U, the TAR-DNA-binding protein 43 (TDP-43), which is normally contained within the nucleus, is expelled from the nucleus Subsequently, deficits in recognizing faces of others became apparent, and he was unaware when his daughters became upset. Four years after diagnosis, comprehension for spoken and written language had disappeared, and he called all people and items in his environment ''thing.'' MMSE score was 1 with the only item performed correctly being the drawing of the intersecting pentagons. Subtle problems with swallowing emerged 5 1 / 2 years after diagnosis, and the patient died 6 months later. At autopsy extensive atrophy of the anterior temporal lobes, orbitofrontal, and medial frontal cortex was evident. Extensive spongiosus, gliosis, and neuronal loss were evident in these frontotemporal regions. Ubiquitin-positive inclusions were evident in the frontal and anterior temporal lobes.
Comment. This patient developed classic symptoms and findings of SD. Like many patients with asymmetric left-sided temporal lobe degeneration, his first symptoms related to naming people and objects. Also typical of other SD patients was his compulsive preoccupation with coins, earrings, solitaire, and tennis. As his disease moved from the left to the right anterior temporal lobe, deficits in the recognition of faces became evident. His abnormalities in object naming and verbal memory in association with sparing of frontal and parietal lobe functions also typify this FTLD subtype.
Continued from page 92
Case 4-3 A 63-year-old woman began to notice trouble finding words. She became quieter and somewhat socially withdrawn. Increasingly, the expression of ideas and words diminished. Deficits in writing paralleled the problems with speech. When talking, she took a long time to express her ideas and communicated agrammatically with nouns and verbs. Others told her that she had trouble ''spitting out words.'' Social graces remained preserved, although she expressed profound frustration regarding her speech, and she developed a major depression. There was no family history of dementia.
On examination the patient was well dressed and polite. Neurologic examination was normal. MMSE was 29/30; she missed the repetition item. Speech was nonfluent with a decreased number of words spoken per minute, short phrase length, and a stuttering output with articulatory groping. Comprehension was normal. Working memory was slightly diminished; she could only repeat four numbers backwards. She generated 18 animals in 1 minute but only 8 d words. The Trail-Making Test Trails B was performed slowly, but no errors were evident. Copying of the Rey-O was precisely performed without error, and after 10 minutes she remembered 14 of 17 points on the drawing. She did well on verbal learning, remembering 9 of 9 words after 10 minutes. She correctly named 55 of 60 words on the Boston Naming Test and got three more with multiple choice. Recognizing facial emotions was normal (Figure 4-4) .
Within 2 years the patient was mute and swallowing deficits emerged. She exhibited frequent falls, particularly when walking down stairs. On examination, inability to look up or down was found and axial rigidity was evident. The patient died within 6 weeks. PSP was seen at pathology.
Comment. This patient began with NFA but soon afterwards exhibited findings suggestive of PSP including falls, the inability to look up or down, and axial rigidity. The association of PSP and CBD with NFA is now well recognized, and the majority of patients with NFA show PSP or CBD on postmortem examination. and accumulates in the cell bodies and processes of neurons (Neumann et al, 2006) . TDP-43 has been identified in sporadic and familial FTLD-U and ALS cases, although subtle differences in the TDP-43 variants may reflect different pathogenic mechanisms in the different disease subtypes. One current topic of research involves delineating the clinical correlates of the FTLD-U syndrome to investigate whether this syndrome should be considered a separate disorder from FTD-MND. Recent work points to a relationship between FTLD-U and SD (Spillantini et al, 2000) . CBD brains have also been shown to have ballooned or swollen neurons similar to those seen in Pick's disease but without Pick bodies. These ballooned neurons may be found through-out the neocortex, but mostly in the superior frontal and parietal lobes, including primary motor or sensory cortex. Neuronal loss and gliosis is also visible in affected regions, often in the basal ganglia. Finally, astrocytic plaques that stain with anti-tau antibodies are found in CBD (Dickson et al, 2002) .
PSP is also associated with tau inclusions in neurons and glia. Neurofibrillary tangles are evident in cortex and midbrain. Cortical atrophy is relatively mild while midbrain and brain stem atrophy is evident (Boxer et al, 2006) .
GENETIC FINDINGS
The reported proportion of FTLD cases with a family history has varied widely. 
KEY POINT:
A Microscopic findings in FTD include neuronal swelling (ballooned cells) and intraneuronal inclusions, which may either be tau-positive, tau-negative but ubiquitinpositive, or rarely both tau-and ubiquitin-negative.
1988
). This variability probably reflects regional differences in the prevalence of genetic mutations but also may reflect the fact that different FTLD subtypes show different patterns of inheritance. In our experience, FTD-MND and FTD are strongly genetic with many cases demonstrating family histories, suggesting an autosomal dominant pattern of inheritance, with fewer NFA and almost no SD cases showing dominant patterns of inheritance (Goldman et al, 2005) . Nonetheless, genetic markers of FTLD are currently being vigorously pursued.
The first important genetic mutations in FTLD were seen in tau. This syndrome is called FTD with parkinsonism linked to chromosome 17 (FTLD-17). FTLD-17 turned out to be associated with mutations in the exon or intron regions of the tau gene localized to 17q21-22 (van Slegtenhorst et al, 2000; Wilhelmsen et al, 1994) . Since the initial discovery, at least 30 distinct pathogenic mutations have been identified in a large number of families with FTLD-17. Three of the mutations account for more than half of the genetically characterized cases currently reported in the literature. These three mutations are the P301L, associated with the classic FTD phenotype, exon 10 5' splice-site +16, associated with a syndrome that includes memory or language impairment and parkinsonism, and N279K, with features of parkinsonism and PSP, also called pallidopontonigral degeneration.
The tau protein binds to microtubules, thereby facilitating microtubule assembly. Via this mechanism, the protein maintains the stability of cytoskeletal structural elements. In a healthy brain, tau is soluble and expressed as six major protein isoforms that are generated by alternative splicing of the gene on chromosome 17q21. Exon 10 controls the number of microtubule binding sites. If it is included (exon 10+) in the messenger RNA (mRNA), then the protein will be formed with four binding domains (4R tau). If excluded (exon 10-), the resulting protein will have only three domains (3R tau). In healthy brains, the ratio of 3R to 4R is 1:1. Many of the tau mutations that are involved in FTLD are clustered around exon 10, with the ultimate result of altering the ratio of 3R to 4R in the brain, or altering the binding affinity of the protein (Hong et al, 1998) .
Further complicating diagnosis, identical genetic mutations may result in different phenotypes. For example, in one family, a tau mutation resulted in a syndrome diagnosed as CBD in the father and as FTD in the son (Bugiani et al, 1999) . In addition to mutations on chromosome 17q21-22, Bird and colleagues (2003) found that FTD may also be linked to chromosome 9q21-q22.
Although the genetic basis of taupositive FTLD is now well established, until recently the genetic basis of taunegative ubiquitin-positive familial FTD had remained a mystery. Many of these kindreds also showed evidence for linkage in the same region of chromosome 17q21 but did not carry tau mutations. Instead of tau inclusions, as described in the microscopic pathology section, many showed ubiquitin (ub)-immunoreactive neuronal cytoplasmic inclusions (Figure 4-6) .
These inclusions were generally found in layer II of frontal and temporal neocortex and in the dentate gyrus of the hippocampus (Neary et al, 2000) . In a recent report by Baker and colleagues (2006) , nine families with FTD conclusively linked to chromosome 17q21 failed to show any of the 30 known tau mutations, but all affected patients showed ub-immunoreactive pathology. In all of these families, missense mutations in progranulin were found to be the cause of FTD (Vadlamudi et al, 1996) . The exact function of
KEY POINT:
A A positive family history is seen in 10% to 50% of patients with FTD with the most common genetic mutations on chromosome 17q21.
progranulin in neurons remains unknown, although outside of the nervous system it is involved in wound repair and mediates inflammation influencing cell-cycle progression and cell motility (He et al, 2003) . It is possible that this 99 FIGURE 4-6 Ubiquitin-immunopositive inclusions. protein has growth factor activity even in the brain: high levels may be tumorigenic while low levels appear to cause FTD. Baker and colleagues (2006) showed that the mutations in FTD cause a loss in functional progranulin (haplo-insufficiency) by creating a null allele. Hence, ubiquitin inclusions do not contain progranulin. This discovery is particularly exciting because it suggests that by replacing progranulin, clinicians may be able to halt the progression of FTD.
A set of rarer mutations has been seen as a cause of autosomal forms of FTD. A mutation in the valosincontaining protein causes a combination of inclusion body myositis, Paget's disease, diabetes, and FTD. In a few families an autosomal form of FTD has been associated with mutations in the CHMP gene involved with endosomal processing of proteins. Still unaccounted for are the large numbers of patients in whom familial FTD-MND occurs. Several groups are close to mapping a gene on chromosome 9 associated with this syndrome.
Genetic Testing Considerations
Presently, as there is no effective therapy to prevent the onset of FTLD-17, families suspected to have the mutations should be referred to genetic counseling before the tests are ordered. Furthermore, since most individuals with FTD do not show a genetic link, clinical genetic testing should only be considered in cases in which there is a clear family history of symptoms. On HMPAO-SPECT, patients with SD show severe, bilateral but asymmetric hypoperfusion in the anterior temporal lobes (Edwards-Lee et al, 1997) . Atrophy is also clearly seen on structural MRI scans, and SD may be differentiated from AD even by visual inspection (Galton et al, 2001) . Chan and colleagues (2001b) have demonstrated that detailed volumetric measures may show that hippocampal atrophy is more severe in SD than in AD, and usually it is asymmetric, accompanied by more severe atrophy of the amygdalae, temporal pole, fusiform, and inferolateral temporal gyri. Mummery and colleagues (1999) have also shown that FGD-PET reveals brain activation changes in regions outside of the temporal lobes, reflecting the disruption that semantic memory impairments cause in other brain regions. Few efforts have been made to distinguish NFA from other subtypes with neuroimaging, but structural MRI has shown left perisylvian atrophy (Hodges and Patterson, 1996; Rosen et al, 2002b) .
IMAGING
A promising new approach to differentiating FTD from AD has come with the new amyloid agent Pittsburgh Compound B (PIB). PIB binds to beta-amyloid proteins in living tissue and may be detected using PET. Since accumulation of beta-amyloid is not a marker of FTLD, PIB imaging may be useful in differentiating FTLD from AD (Figure 4-7) .
TREATMENT AND THERAPY
Unfortunately, no effective pharmacologic treatments are available to reverse or halt the progression of FTLD. Current treatment of patients with FTD involves treating specific symptoms and improving quality of life. Acetylcholinesterase inhibitors developed to improve symptoms of AD do not seem to be effective in managing symptoms of FTD, perhaps because the cholinergic neurons in the nucleus basalis of Meynert are relatively spared in FTLD. Furthermore, acetylcholinesterase inhibitors may cause agitation in patients with FTLD and are particularly dangerous for patients with FTD-MND, since they may cause increased production of oral secretions.
Selective serotonin reuptake inhibitors (SSRIs), in contrast, have shown some success in treating compulsions and carbohydrate cravings in patients with FTLD (Swartz et al, 1997) . Generally, SSRIs are well tolerated by patients. Patients who do not respond to SSRIs and who show aggressive or delusional behaviors may benefit from low doses of atypical antipsychotics such as olanzapine, quetiapine, or risperidone. Typical antipsychotics known to result in extrapyramidal side effects should be avoided, since patients with FTLD are likely to show parkinsonism. In the only placebo-controlled study of FTLD, the antidepressant trazodone was shown to be effective compared with placebo in controlling behavior (Pasquier et al, 2003) .
Because behavioral changes figure prominently in the disease, the safety of the patient and those with whom the patient interacts must be a primary concern. Removing dangerous items from the home, eliminating driving later in the disease, and educating caregivers are all methods of prevent-ing injury and distress. In addition to education, caregivers should also be provided with support and respite. Depression in caregivers is common and leads patients to earlier nursing home placement (Litvan, 2001) .
FUTURE DIRECTIONS
Many challenges associated with FTLD and related disorders remain. Finally recognized as important, relatively common, and distinctive from AD, FTLD research has accelerated in recent years. It is becoming evident that the three major FTLD subtypes have distinctive demographics, rates of progression, and possibly even etiologies. As diagnosis has improved, new challenges have emerged. Even at research centers, many patients diagnosed with FTLD turn out to have AD on pathologic examination, and close to perfect separation of these two disorders remains a goal of the coming decade. A further challenge for clinicians, we suspect, is that in the future diagnoses will separate tau-related FTLD from ubiquitinrelated FTLD as distinctive therapies for these subtypes are developed. Whenever therapies become available, more accurate and earlier diagnosis of FTLD will be needed.
The recent discovery of the progranulin gene mutation as a cause for FTD has caused great excitement in the field. Unlike tau mutations, the progranulin mutation may be relatively common, which may require more widespread screening for this mutation in patients with FTD. Importantly, the potential for therapy has been stimulated by this finding since progranulin appears to have growth factor activity. Other therapeutic approaches are under active study in animal models of FTLD associated with tau and valosin mutations. Finally, the FTD-ALS gene or genes will soon be discovered, offering still new hopes and challenges.
